Sara Saltzman - Cogent Biosciences VP Affairs

Cogent Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.74 in 2025. Return On Capital Employed is likely to drop to -0.91 in 2025. At this time, Cogent Biosciences' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.1 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 186.6 M in 2025.

Similar Executives

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. Cogent Biosciences (COGT) is traded on NASDAQ Exchange in USA. It is located in 275 Wyman Street, Waltham, MA, United States, 02451 and employs 164 people. Cogent Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cogent Biosciences Leadership Team

Cogent Stock Performance Indicators

Additional Tools for Cogent Stock Analysis